Trial Profile
Combination of Brutons Tyrosine Kinase (BTK) Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant Acute Myeloid Leukemia (AML)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Aclacinomycin B; Cytarabine; Decitabine; Granulocyte colony-stimulating factors; Sorafenib
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 29 Aug 2018 New trial record